SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Indoco Remedies - Quaterly Results

02 Nov 2021 Evaluate
The company witnessed a 17.99% growth in the revenue at Rs. 3865.90 millions for the quarter ended September 2021 as compared to Rs. 3276.50 millions during the year-ago period.Handsome Net Profit growth of 65.55% reported above the corresponding previous quarter figure of Rs. 415.70 millions to Rs. 251.10 millions.OP of the company witnessed a marginal growth to 873.30 millions from 607.00 millions in the same quarter last year.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202109 202009 % Var 202109 202009 % Var 202103 202003 % Var
Sales 3865.90 3276.50 17.99 7730.80 6035.10 28.10 12403.00 11060.00 12.14
Other Income 10.10 5.20 94.23 18.70 7.80 139.74 31.20 24.30 28.40
PBIDT 873.30 607.00 43.87 1750.00 1098.20 59.35 2266.90 1257.70 80.24
Interest 30.60 58.90 -48.05 72.90 116.40 -37.37 222.20 262.50 -15.35
PBDT 842.70 548.10 53.75 1677.10 981.80 70.82 2044.70 995.20 105.46
Depreciation 194.60 185.70 4.79 416.90 377.00 10.58 731.20 708.10 3.26
PBT 648.10 362.40 78.84 1260.20 604.80 108.37 1313.50 287.10 357.51
TAX 232.40 111.30 108.81 448.40 181.40 147.19 389.60 44.60 773.54
Deferred Tax -30.80 -52.10 -40.88 -88.40 -97.30 -9.15 4.90 44.60 -89.01
PAT 415.70 251.10 65.55 811.80 423.40 91.73 923.90 242.50 280.99
Equity 184.30 184.30 0.00 184.30 184.30 0.00 184.30 184.30 0.00
PBIDTM(%) 22.59 18.53 21.94 22.64 18.20 24.40 18.28 11.37 60.72

Indoco Remedies Share Price

228.20 -23.05 (-9.17%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×